Francisco Arath Ruiz-Velázquez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Francisco Arath Ruiz-Velázquez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ana Lilia González-Yebra
Departamento de Ciencias Aplicadas al Trabajo, División Ciencias de la Salud, Universidad de Guanajuato, Campus León, León 37670, Guanajuato, Mexico
2 shared publications - Beatriz González-Yebra
Department of Medicine and Nutrition, Division of Health Sciences, University of Guanajuato, Campus León, León 37670, Guanajuato, Mexico
2 shared publications - Anaid Herrerías-García
Departamento de Medicina y Nutrición, División Ciencias de la Salud, Universidad de Guanajuato Campus León. León, Guanajuato, México
1 shared publication - Anaid Herrerías-García
Metabolic Research Laboratory, Department of Medicine and Nutrition, University of Guanajuato, León, Guanajuato, Mexico
1 shared publication - Daniela Beatriz Muñoz-López
Departamento de Medicina y Nutrición, Universidad de Guanajuato, León, México
1 shared publication - Elia Lara-Lona
Department of Medicine, University of Guanajuato, Leon, Mexico
1 shared publication
Latest Publications
- Open Access
Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the presence of the Philadelphia chromosome, a product of the reciprocal translocation t(9;22)(q34;q11), in the BCR and ABL genes. These rearrangements in both genes lead to the formation of various fusion mRNA products, with preferential expression of b2a2, b3a2, and other BCR::ABL1 mRNA variants, combined with additional chromosomal abnormalities. Notably, the distribution and frequency of different mRNA variants vary in different populations. However, studies concerning this in Mexico are limited, and the results have been inconclusive. This study therefore aimed to determine the distribution of BCR::ABL1 mRNA variants in different clinical phases of CML and their effect on hematological parameters and patient survival. This study included 33 patients, whose demographic, clinical, and molecular data on BCR::ABL1 mRNA variants and hematological parameters were collected to identify potential associations. A total of 84.8% (n = 28) of patients had BCR::ABL1 translocation and increased platelet and basophil counts. The most frequent mRNA variant was b3a2 (64.3%), followed by b2a2 (28.6%) and e1a2 (3.6%). Concerning the clinical phases of CML, 75.8% (n = 25), 21.2% (n = 7), and 3% (n = 1) of patients were in the chronic, blast, and accelerated phases, respectively. Moreover, the b3a2 mRNA variant was more commonly identified in patients in the chronic phase. No correlation was observed between mRNA variant expression and patient survival. However, b2a2 was indicative of patients with longer survival as well as those treated with imatinib or nilotinib. Additionally, platelet count could be a marker of BCR::ABL1 translocation.
Open AccessDistribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the presence of the Philadelphia chromosome, a product of the reciprocal translocation t(9;22)(q34;q11), in the BCR and ABL genes. These rearrangements in both genes lead to the formation of various fusion mRNA products, with preferential expression of b2a2, b3a2, and other BCR::ABL1 mRNA variants, combined with additional chromosomal abnormalities. Notably, the distribution and frequency of different mRNA variants vary in different populations. However, studies concerning this in Mexico are limited, and the results have been inconclusive. This study therefore aimed to determine the distribution of BCR::ABL1 mRNA variants in different clinical phases of CML and their effect on hematological parameters and patient survival. This study included 33 patients, whose demographic, clinical, and molecular data on BCR::ABL1 mRNA variants and hematological parameters were collected to identify potential associations. A total of 84.8% (n = 28) of patients had BCR::ABL1 translocation and increased platelet and basophil counts. The most frequent mRNA variant was b3a2 (64.3%), followed by b2a2 (28.6%) and e1a2 (3.6%). Concerning the clinical phases of CML, 75.8% (n = 25), 21.2% (n = 7), and 3% (n = 1) of patients were in the chronic, blast, and accelerated phases, respectively. Moreover, the b3a2 mRNA variant was more commonly identified in patients in the chronic phase. No correlation was observed between mRNA variant expression and patient survival. However, b2a2 was indicative of patients with longer survival as well as those treated with imatinib or nilotinib. Additionally, platelet count could be a marker of BCR::ABL1 translocation.
- Open Access
- 2 January 2023
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 65 (1, ene-feb) , 107
Análisis de la presencia de trisomía 8 en las diferentes fases de leucemia mieloide crónica
- 2 January 2023
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 65 (1, ene-feb) , 107
Open AccessAnálisis de la presencia de trisomía 8 en las diferentes fases de leucemia mieloide crónica